2MDG

Solution NMR Structure of Zinc finger protein 423 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR7298F

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
2	2D 1H-13C HSQC aliphatic	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
3	3D HNCO	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
4	3D CBCA(CO)NH	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
5	3D HNCACB	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
6	3D H(CCO)NH	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
7	3D HCCH-TOCSY	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
8	3D 1H-15N NOESY	0.51 mM [U-5% 13C; U-100% 15N] HR7298F.009, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	95% H2O/5% D2O	100	6.5	ambient	298
9	3D 1H-13C NOESY aliphatic	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
10	2D 1H-13C CT HSQC	0.51 mM [U-5% 13C; U-100% 15N] HR7298F.009, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	95% H2O/5% D2O	100	6.5	ambient	298
11	2D 1H-15N J-modulation HSQC	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
12	2D 1H-15N J-modulation HSQC	0.51 mM [U-5% 13C; U-100% 15N] HR7298F.0059, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 4.2 % C12E5 PEG/Hexanol, 50 uM ZnSO4	95% H2O/5% D2O	100	6.5	ambient	298
13	2D 1H-15N CO filtered TROSY	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4	90% H2O/10% D2O	100	6.5	ambient	298
14	2D 1H-15N CO-filtered TROSY	0.17 mM [U-100% 13C; U-100% 15N] HR7298F.005, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % [U-100% 2H] D2O, 50 uM DSS, 50 uM ZnSO4, 4.2 % C12E5 PEG?Hexanol	90% H2O/10% D2O	100	6.5	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Varian	INOVA	600
2	Varian	Avance	900
3	Varian	Avance	600

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (fewest violations)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinemen,structure solution,geometry optimization	CNS	1.3	Brunger, Adams, Clore, Gros, Nilges and Read
2	structure solution	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
3	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
4	collection	VNMRJ		Varian
5	chemical shift assignment	SPARKY	3.113	Goddard
6	structure validation	PALES		PALES (Zweckstetter, Bax)
7	structure validation	PSVS	1.5	Bhattacharya, Montelione
8	refinement	CNS

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.